Interaction Between Drug and Stent Randomization 1-Year Stent Endpoints (N=3006) Kaplan-Meier estimates TAXUS(N=2257)EXPRESS(N=749) HR [95%CI] P int Ischemic TLR, all 4.5%7.5% 0.59 [0.43,0.83] - - UFH + GPI subgroup - UFH + GPI subgroup3.3%7.9% 0.42 [0.25,0.68] 0.17 - Bivalirudin subgroup - Bivalirudin subgroup5.6%7.1% 0.78 [0.50,1.24] Safety MACE, all* 8.1%8.0% 1.02 [0.76, 1.36] - - UFH + GPI subgroup - UFH + GPI subgroup8.2%8.8% 0.92 [0.66,1.27] 0.89 - Bivalirudin subgroup - Bivalirudin subgroup8.0%7.2% 1.17 [0.83,1.64] Binary restenosis, all** 10.0%22.9% 0.44 [0.33, 0.57] - - UFH + GPI subgroup - UFH + GPI subgroup10.9%19.2% 0.57 [0.38,0.84] 0.18 - Bivalirudin subgroup - Bivalirudin subgroup9.2%26.7% 0.34 [0.24,0.49] *Death, reinfarction, stroke or stent thrombosis **1081 lesions in the TAXUS group, 332 in the EXPRESS group